Research Article
Significance of PPARA as a Treatment Target for Chronic Lymphocytic Leukemia
Table 1
Characteristics of 86 newly diagnosed chronic lymphoblastic leukemia patients.
| | Characteristics | N (%) |
| | Sex | | | Male | 61 (70.93%) | | Female | 25 (29.07%) | | Age (year) | | | <45 | 9 (10.46%) | | ≥45, <65 | 51 (59.30%) | | ≥65 | 26 (30.23%) | | CLL-IPI | | | Low/intermediate risk | 74 (86.05%) | | High risk | 12 (13.95%) | | FISH | | | del(13q) | 12 (13.95%) | | del(11q) | 13 (15.11%) | | del(17p) | 5 (5.81%) | | Trisomy 12 | 2 (2.32%) | | TP53(NGS) | | | TP53 mutation | 5 (5.81%) | | TP53 wt | 78 (90.70%) | | Unknown | 3 (3.49%) | | IGHV | | | Mutated | 61 (70.93%) | | Unmutated | 25 (29.07%) | | Bulky disease | 9 (10.465%) | | Extranodal involvement | 5 (5.814%) | | Hepatomegaly | 5 (5.814%) | | Splenomegaly | 42 (48.837%) | | Initial WBC (×109/L) | | | >100 | 3 (3.488%) | | 50–100 | 15 (17.442%) | | <50 | 68 (79.07%) | | Initial HGB (g/L) | | | >110 | 69 (80.233%) | | 90–110 | 11 (12.791%) | | <90 | 6 (6.977%) | | Initial PLT (×109/L) | | | ≥100 | 77 (89.535%) | | <100 | 9 (10.465%) | | Initial LYM (%) | | | >80 | 44 (51.163%) | | 50–80 | 31 (36.047%) | | <50 | 11 (12.791%) | | Initial LYMC (×109/L) | | | >100 | 3 (3.488%) | | 50–100 | 8 (9.302%) | | <50 | 75 (87.209%) |
|
|
